CARLSBAD, Calif., April 7 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announces the following webcast:
What: Isis and Symphony GenIsis Collaboration Conference Call
When: Monday, April 10, 2006 at 8:30 a.m. ET / 5:30 a.m. PT
Where: http://www.isispharm.com/
How: Live on the Internet. Simply log onto our website listed above.
Contact: Claudine Prowse, Ph.D.
Executive Director, Corporate Development
(760) 603-2331
If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at http://www.isispharm.com/.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 14 antisense drugs in development to treat cardiovascular, metabolic, inflammatory and ocular diseases, and cancer. In its Ibis division, Isis is developing and commercializing the TIGER biosensor system, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of approximately 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com/.
This webcast includes forward-looking statements regarding the development, therapeutic potential and safety of ISIS 301012, and the antisense drugs targeted to GCCR and GCGR, and the potential success of the collaboration with Symphony GenIsis, Inc. Any statement describing Isis' goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward- looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2005, which is on file with the U.S. Securities and Exchange Commission (SEC) and available from the Company.
